Back to results
US 11,446,291 B2Granted
Methods for the treatment of abnormal involuntary movement disorders
AssigneeAuspex Pharmaceuticals, Inc.
InventorsDavid Stamler, Michael Fangching Huang
Life of this patent
Estimating the term…
Abstract
Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
Claims30
A method of transitioning a human from tetrabenazine to deutetrabenazine for the treatment of tardive dyskinesia, comprising:
- a) discontinuing a daily amount of tetrabenazine;
- and
- b) administering an initial daily amount of deutetrabenazine the next day to the human,
- wherein the daily amount of tetrabenazine is 12.5 mg and the initial total daily amount of deutetrabenazine is 6 mg;
- or
- wherein the daily amount of tetrabenazine is 25 mg and the initial total daily amount of deutetrabenazine is 12 mg;
- or
- wherein the daily amount of tetrabenazine is 37.5 mg and the initial total daily amount of deutetrabenazine is 18 mg;
- or
- wherein the daily amount of tetrabenazine is 50 mg and the initial total daily amount of deutetrabenazine is 24 mg;
- or
- wherein the daily amount of tetrabenazine is 62.5 mg and the initial total daily amount of deutetrabenazine is 30 mg;
- or
- wherein the daily amount of tetrabenazine is 75 mg and the initial total daily amount of deutetrabenazine is 36 mg;
- or
- wherein the daily amount of tetrabenazine is 87.5 mg and the initial total daily amount of deutetrabenazine is 42 mg;
- or
- wherein the daily amount of tetrabenazine is 100 mg and the initial total daily amount of deutetrabenazine is 48 mg.
15 more elements
Dependencies are inferred from the claim text.